Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Drug treatment in pregnancy
Autore:
Thurmann, PA; Steioff, A;
Indirizzi:
Univ Witten Herdecke, Philipp Klee Inst Clin Pharmacol, Witten, Germany Univ Witten Herdecke Witten Germany nst Clin Pharmacol, Witten, Germany
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
fascicolo: 5, volume: 39, anno: 2001,
pagine: 185 - 191
SICI:
0946-1965(200105)39:5<185:DTIP>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROSPECTIVE COHORT; 1ST TRIMESTER; WOMEN; PHARMACOKINETICS; EXPOSURE; ISOTRETINOIN; PHYSICIANS; PREVENTION; OUTCOMES; THERAPY;
Keywords:
pregnancy; drug treatment; pharmacoepidemiology;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Thurmann, PA Hosp Wuppertal GmbH, Philipp Klee Inst Clin Pharmacol, Heusnerstr 40, D-42283 Wuppertal, Germany Hosp Wuppertal GmbH Heusnerstr 40 Wuppertal Germany D-42283
Citazione:
P.A. Thurmann e A. Steioff, "Drug treatment in pregnancy", INT J CL PH, 39(5), 2001, pp. 185-191

Abstract

When considering drug therapy in pregnancy, the risk of treatment for the embryo/fetus has to be weighed against the risk to the mother and the childof carrying out no treatment. This is of particular relevance in certain conditions like diabetes, epilepsy or AIDS, where the risk of embryopathy isincreased when no treatment is carried out and the available drugs are potentially teratogenic. However, carefully selected drugs and close meshed monitoring may even decrease the risk for the child. In many instances, unintentional drug exposure occurs in the period before the pregnancy has been diagnosed. This may lead to additional diagnostic measures or even abortion of an otherwise wanted child. In both situations, planned and unintentionaldrug exposure during pregnancy, insufficient information is available on the clinical conditions relevant here and the specific drugs involved. Identification of potential teratogenic effects of a new drug takes place duringthe early development phase. However, animal models may not be representative of specifically human characteristics, e.g. deficiences in enzymes. Since drug treatment is generally best avoided during pregnancy, pharmacokinetic studies in this population are rare. However, physiological changes, known to be relevant for some drugs do occur during pregnancy. In order to improve knowledge on the pharmacokinetics of drugs in pregnancy, population pharmacokinetic approaches may represent a Solution. Intensive efforts to investigate the efficacy and safety of drugs during pregnancy are necessary. Since controlled clinical trials are usually not feasible due to ethical reasons, intensified collection of case reports as well as epidemiological studies are warranted to gain sufficient information for the counselling of pregnant women.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 07:50:54